The biotech company Morphosys positions itself for further growth in the USA with an acquisition worth billions. The Bavarian pharmaceutical enterprise buys the US biotech company Constellation Pharmaceuticals, which specialises in cancer therapies, as Morphosys announced. They value Constellation’s equity at 1.7 billion US dollars, or about 1.4 billion euros. The takeover is being financed with several components by the financial company Royalty Pharma.
The actual deal involves several stages: The takeover offer for all existing Constellation shares will be made in a first step via an indirectly held, wholly owned Morphosys subsidiary. In a second step, the company then wants to take over the rest as part of a merger.
This text is a press release from JUVE. The full text version of the article can be found here: https://www.juve.de/nachrichten/deals/2021/06/milliardenpartnerschaft-morphosys-greift-mit-skadden-und-ungewoehnlicher-finanzierung-nach-us-pharmakonzern